However, the DPP-4 inhibitor linagliptin increases the CX3CR1-positive monocytes with enhanced putative vasculoregenerative cells in type 2 diabetes patients with or without DN [19]. This evidence concerns the gene CX3CR1 and liver dysplastic nodule.